Bharat Parenter. — Q4 FY25 earnings call

Call held 14 May 2025

Management summary

Bharat Parenterals Limited reported strong financial growth in FY25, driven by both standalone and consolidated performance. The flagship CDMO subsidiary, Innoxel Lifesciences, achieved a critical US FDA inspection milestone and aims for operational break-even in FY26. The company is expanding its product pipeline and investing in new facilities for emerging markets, while managing debt and improving working capital.

Highlights

  • FY25 Standalone Revenue: INR 318.7 crores, up 19.8% YoY.

  • Q4 FY25 Standalone Revenue: INR 82.54 crores, up 20% YoY.

  • FY25 Consolidated Revenue: INR 352 crores, up 32% YoY.

  • FY25 EBITDA: INR 48.14 crores, up 17% YoY, with EBITDA margin at 15.9% (flat YoY).

  • FY25 PAT: INR 26.58 crores, up 17% YoY.

  • Innoxel Lifesciences completed its first US FDA inspection with only one minor observation.

  • Innoxel targets operational break-even in FY26 with INR 70 crores in milestone payments.

  • Bharat Parenterals increased its stake in Innoxel to 56% for INR 65 crores.

Key financials

3 periods

Headline

  • Total Debt
    ₹180 Cr
  • Trade Receivables
    ₹172 Cr

Q4 FY25

  • Standalone Revenue
    ₹82.54 Cr
    YoY +20%

FY25

  • Standalone Revenue
    ₹318.7 Cr
    YoY +19.8%
  • Consolidated Revenue
    ₹352 Cr
    YoY +32%
  • EBITDA
    ₹48.14 Cr
    YoY +17%
  • EBITDA Margin
    15.9%
    YoY 0%
  • PAT
    ₹26.58 Cr
    YoY +17%

What they filed

Q1 FY27: revenue down 19.2%, net profit down 309.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue72 72 104 116 65 −10%65 −10%100 −4%94 −19%
EBITDA-8 4 2 14 1 +111%2 −52%-1 −123%9 −38%
Net profit-18 -8 -9 -1 -9 +51%-10 −23%-8 +14%-4 −309%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • Capex Capex disclosed
    • Innoxel Lifesciences facility (total capex) ₹250 Cr
    • Varenyam Bio Lifesciences facility (total projected capex) ₹120 Cr
    • Varenyam Bio Lifesciences facility (already spent) ₹30 Cr
    • BPL facility upgrades to meet revised Schedule M ₹14 Cr
    Innoxel: "the broad ballpark number is INR250 crores, correct. The Gross Block, if I have to consider the land and the plant and machinery, would be roughly around INR200 crores. And the capex costs would be around the balance of it, which would be comprising of R&D as well as employee costs." (Page 9); Varenyam Bio Lifesciences: "Varenyam Bio Life Sciences, we have projected the overall project to be between INR120 crores to INR150 crores. And that's the extent of it based on the lines that we have targeted as of now. Around INR30 crores is already spent." (Page 9); BPL: "we have spent almost INR14 crores plus in last 13, 14 months, which has taken care to upgrade, meet the revised Schedule M" (Page 13)
  • Debt Gross ₹180 Cr Cost 6.5%
    Debt: "INR180 crores debt also to service." (Page 12); Cost of debt: "our average cost of, I mean, on the interest is not significantly increased. This year it is increased by INR1 crores. Again, the 5.5, it is around 6.5 if I'm not wrong." (Page 12)
  • M&A Innoxel Lifesciences Acquisition · Closed · Consideration ₹[object Object] (cash)

    Increased stake in flagship CDMO company to 56%.

    we took additional 10% stake at Innoxel, taking Bharat Parental's overall percentage at 56%. (Page 7); We put in roughly around INR65 crores for an additional 10% stake at Innoxel. (Page 17)
  • Liquidity Liquidity disclosed Expected significant reduction in bank fund utilization due to realization of older trade receivables.
    I'm more than sure that that will reduce significantly because we will get these realization and the utilization of the bank fund will be reduced a lot. (Page 13)

Guidance & targets

Profitability

  • Innoxel Net Margins (US/EU business) Profitability · long-term · High confidence higher of 30%
    But I can say that the margins would be higher of 30% net at Innoxel for the US and the EU business.

    — Bhahim Desai

  • Innoxel Operational Break-even Profitability · FY26 · High confidence operational break-even
    Right now, we are looking to operationally break even in this FY '26 at Innoxel. And INR70 crores in terms of our top line revenue would be enough for us to operationally break even

    — Bhahim Desai

Revenue

  • Innoxel Milestone Payments Revenue · this year (FY26) · High confidence INR 70 crores
    We are only looking for the milestone payments in this year, which, like sir said, would be around INR70 crores.

    — Bharat R. Desai

  • Innoxel Peak Revenues Revenue · 2030 to 2031 (next 5 to 6 years) · High confidence INR 750 crores
    I would say towards the peak of the organization, we are looking at an asset turnover of maybe three to four times of the current levels that we've invested in. So that's broadly what I can say at this moment. So this three to four is basically, so on INR250 crores you're saying about 750 is what we can generate, is it? At peak. So we're looking to reach around that point in the next 5 to 6 years. So 2030 to 2031 is when we are looking at our peak revenues.

    — Bhahim Desai

Capacity

  • Innoxel Product Pipeline Capacity · next three to four years · High confidence 40 to 45 products

    From 20 to 22 products today

    Initially, we started with 20 to 22 products in the development pipeline and the management is aiming to take this number to around 40 to 45 products over the next three to four years.

    — Bhahim Desai

  • Innoxel EU GMP Audits Capacity · H1 FY26 · High confidence completed
    The EU GMP audits at the site are lined up for FY26 with confirmed dates in H1 of FY26.

    — Bhahim Desai

  • Varenyam Biolifesciences Operational Status Capacity · by 2027 · High confidence operational
    The plant is expected to be operational by 2027 and the current pace of construction is in line with the same.

    — Bhahim Desai

Margin

  • BPL ROW Markets Margins Margin · ongoing · High confidence 25% to 35%
    The margins are always quite tight, but typically we work within a broad margin of 25% to 35% percent on export oriented orders.

    — Bhahim Desai

  • BPL Domestic Markets Margins Margin · ongoing · High confidence 30% to 35%
    we would be roughly around 30% to 35% in terms of margins when we talk about domestic business.

    — Bhahim Desai

  • Varenyam Healthcare EBITDA Margins Margin · ongoing · High confidence 30% to 35%
    Varenyam Healthcare broadly operates in between 30% to 35% or 30% to 40% of margin, depending on various products and various brands. So that's the broad category of margins. But yes, 30 to 35 would be an average margin that I can tell you.

    — Bhahim Desai

What to watch in Q1 FY26

Collection of older trade receivables

Before Q1 FY26 end
Current INR 65-70 crores outstanding from Mozambique and Ghana
Target Full collection

Why it matters

Successful collection will significantly reduce debt and improve the company's liquidity position.

I'm more than sure that before the end of the first quarter, we will receive the entire sum.

Risks & concerns

  • Collection of older trade receivables

    medium

    INR 65-70 crores outstanding for >6 months from Mozambique and Ghana due to elections, expected to be collected by Q1 FY26 end.

    Management acknowledged

  • Timing of CMO revenue realization

    low

    CMO revenue is dependent on partner filings and regulatory approvals, leading to potential delays, hence not included in FY26 projections.

    Management acknowledged

Q&A highlights

8 direct
Innoxel and Varenyam margins Direct
the margins would be higher of 30% net at Innoxel for the US and the EU business. These would be a little bit lower in terms of marginalization in comparison to the US.

Clarifies the expected net margin profiles for the company's key growth drivers in different markets.

Asked by Dhvij Patel

Innoxel ownership and partners Direct
That was before the last round where we had right of first refusal and we took additional 10% stake at Innoxel, taking Bharat Parental's overall percentage at 56%. We only are working with one other group. It's a technocrat group by the name of Seven Oaks.

Provides clarity on the current ownership structure of Innoxel and identifies the key strategic partner.

Asked by Dhvij Patel

Innoxel out-licensing revenue recognition and FY26 projections Direct
what we have projected in this coming year for Innoxel, we are not counting the CMO revenues in this year. We are only looking for the milestone payments in this year, which, like sir said, would be around INR70 crores.

Clarifies the revenue recognition strategy for Innoxel's out-licensing deals and provides a specific revenue target for FY26, excluding CMO business.

Asked by Dhruvesh Sanghvi

Innoxel capex breakdown and future plans Direct
the broad ballpark number is INR250 crores, correct. The Gross Block, if I have to consider the land and the plant and machinery, would be roughly around INR200 crores. And the capex costs would be around the balance of it, which would be comprising of R&D as well as employee costs. So I would like to say that we don't have any planned capex in this coming year as of now.

Details the significant investment made in Innoxel and confirms no major capex is planned for the facility in the immediate future, indicating a focus on operationalization.

Asked by Dhruvesh Sanghvi

Varenyam Bio Lifesciences capex and timeline Direct
Varenyam Bio Life Sciences, we have projected the overall project to be between INR120 crores to INR150 crores. And that's the extent of it based on the lines that we have targeted as of now. Around INR30 crores is already spent. And rest is under, as we speak, is under construction. The plant is expected to be operational by 2027.

Outlines the investment and timeline for the new subsidiary focused on emerging markets, providing visibility into future growth avenues.

Asked by Dhruvesh Sanghvi

Innoxel's product pipeline and IP ownership Direct
Innoxel since start, there is one thing that we have been very clear on that Innoxel will not be owning the ANDAs or the 55B2 registrations. That would be on our partners. We would be partnering before at various stages of development and then ultimately the filing of the product would be our partner's responsibility.

Clarifies Innoxel's CDMO business model, emphasizing that partners retain IP ownership, which impacts revenue streams (licensing fees, profit share) rather than direct product sales.

Asked by Dhwanil Desai

Trade receivables and debt management Direct
I can roughly tell you around INR65, INR70 CR is older than, you know, 6 months, 180 days. And mainly there are the two government supplies. One is at Mozambique and one is at Ghana... I'm more than sure that before the end of the first quarter, we will receive the entire sum. And if you see that our average cost of, I mean, on the interest is not significantly increased. This year it is increased by INR1 crores. Again, the 5.5, it is around 6.5 if I'm not wrong.

Addresses concerns about working capital and debt, providing a clear plan for receivable collection and confirming stable cost of debt.

Asked by Gaurav Agrawal

Innoxel peak revenue potential and timeline Direct
I would say towards the peak of the organization, we are looking at an asset turnover of maybe three to four times of the current levels that we've invested in. So this three to four is basically, so on INR250 crores you're saying about 750 is what we can generate, is it? At peak. So we're looking to reach around that point in the next 5 to 6 years. So 2030 to 2031 is when we are looking at our peak revenues.

Provides a long-term vision for Innoxel's revenue generation capacity and the timeline for achieving it, crucial for valuation models.

Asked by Sagar Arya

2 min read 6 chapters

Detailed narrative

Strong Financial Performance in FY25

Bharat Parenterals Limited reported a robust financial performance for FY25. Standalone revenues grew by 19.8% to INR 318.7 crores, while consolidated revenues saw a significant 32% increase to INR 352 crores. EBITDA for FY25 stood at INR 48.14 crores, marking a 17% growth, with PAT also increasing by 17% to INR 26.58 crores, indicating stable profitability.

Innoxel Lifesciences: CDMO & Regulatory Milestones

Innoxel Lifesciences, the company's flagship CDMO subsidiary, achieved a critical milestone by successfully completing its first US FDA inspection with only one minor observation. This facility, built over four years with a total capex of INR 250 crores, focuses on complex injectables, oncology products, and 505b2 molecules. Furthermore, EU GMP audits are scheduled for H1 FY26, which will enable commercial manufacturing for European markets.

Innoxel Business Model and Revenue Outlook

Innoxel operates on a dual model: CDMO (out-licensing in-house developed products) and CMO (manufacturing client-developed products). For FY26, Innoxel projects INR 70 crores in milestone payments from out-licensing agreements and aims for operational break-even. Long-term, Innoxel targets net margins of over 30% for its US/EU business and expects to reach peak revenues of INR 750 crores by 2030-2031, representing 3-4 times asset turnover on its invested capital.

Varenyam Healthcare and Biolifesciences Expansion

Varenyam Healthcare continues its growth in the domestic market, specializing in critical care, anesthesia, and pain management, maintaining EBITDA margins of 30-35%. The company is also establishing Varenyam Biolifesciences, a new project targeting regulated emerging markets in LATAM, Africa, and Oceania. This facility is currently under construction, with INR 30 crores already spent out of a projected INR 120-150 crores total capex, aiming for operational status by 2027.

Capital Allocation and Debt Management

Bharat Parenterals increased its stake in Innoxel Lifesciences by an additional 10% for INR 65 crores, bringing its total ownership to 56%. The company's total debt stands at INR 180 crores, with an average cost of debt around 6.5%. Management anticipates a significant reduction in debt by the end of Q1 FY26, driven by the expected collection of INR 65-70 crores in older trade receivables from Mozambique and Ghana.

Product Portfolio and Market Strategy

The company maintains a strategic focus on complex injectables and critical care products across its entities. BPL's standalone business is balanced with a 50% institutional and 50% non-institutional split, achieving 25-35% margins on export-oriented orders and 30-35% margins in the domestic market. Innoxel's product pipeline is targeted to expand from 20-22 to 40-45 products over the next 3-4 years, with a healthy mix of 60% injectables and 40% oral liquids.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls